BAY 2666605 是一种具有口服活性的 PDE3A 和 PDE3B 抑制剂，IC50 分别为 87 nM 和 50 nM。BAY 2666605 是一种 PDE3A-SLFN12 复合诱导剂 (WO2019025562A1; example 135)。
货号:ajcx38132
CAS:2275774-60-0
分子式:C17H12F4N2O2
分子量：352.28
溶解度:N/A
纯度：98%
存储：Store at -20°C
库存：现货

Background:

BAY 2666605 is an orally active PDE3A and PDE3B inhibitor with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 is a PDE3A-SLFN12 complex inducer (WO2019025562A1; example 135)[1].

BAY 2666605 (example 135) has anticancer effects, potently inhibit brain cancer(especially glioma, more specifically glioblastoma, astrocytoma), breast cancer (especially ductal carcinoma and adenocarcinoma), cervical cancer, AML(especially erythroleucemia), lung cancer(especially NSCLC adenocarcinoma and SCLC), skin cancer(especially melanoma), oesophagus cancer (especially squamous cell carcinoma), ovarian cancer, (especially teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer[1].

BAY 2666605 (5 mg/kg; p.o; twice daily) teatment shows anti-tumor efficacy in murine xenotransplantation models of human cancer[1].

[1]. Manuel ELLERMANN, et al. Dihydrooxadiazinones. WO2019025562A1.